Cargando…

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide dire...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosewell Shaw, Amanda, Suzuki, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160535/
https://www.ncbi.nlm.nih.gov/pubmed/30298067
http://dx.doi.org/10.3389/fimmu.2018.02103
_version_ 1783358785699446784
author Rosewell Shaw, Amanda
Suzuki, Masataka
author_facet Rosewell Shaw, Amanda
Suzuki, Masataka
author_sort Rosewell Shaw, Amanda
collection PubMed
description Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide direct cancer cell lysis, stimulate systemic immune responses, and have the capacity to provide therapeutic transgenes. Oncolytic virotherapy has shown great promise in many preclinical solid tumor models and the first oncolytic virus has been approved by the FDA for the treatment of advanced melanoma. As monotherapies for solid tumors, oncolytic virotherapy provides only moderate anti-tumor effects. However, due to their complementary modes of action, oncolytic virus and T-cell therapies can be combined to overcome the inherent limitations of each agent. This review focuses on the aspects of oncolytic viruses that enable them to synergize with adoptive T-cell immunotherapies to enhance anti-tumor effects for solid tumors.
format Online
Article
Text
id pubmed-6160535
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61605352018-10-08 Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment Rosewell Shaw, Amanda Suzuki, Masataka Front Immunol Immunology Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies. Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest. Oncolytic viruses provide direct cancer cell lysis, stimulate systemic immune responses, and have the capacity to provide therapeutic transgenes. Oncolytic virotherapy has shown great promise in many preclinical solid tumor models and the first oncolytic virus has been approved by the FDA for the treatment of advanced melanoma. As monotherapies for solid tumors, oncolytic virotherapy provides only moderate anti-tumor effects. However, due to their complementary modes of action, oncolytic virus and T-cell therapies can be combined to overcome the inherent limitations of each agent. This review focuses on the aspects of oncolytic viruses that enable them to synergize with adoptive T-cell immunotherapies to enhance anti-tumor effects for solid tumors. Frontiers Media S.A. 2018-09-21 /pmc/articles/PMC6160535/ /pubmed/30298067 http://dx.doi.org/10.3389/fimmu.2018.02103 Text en Copyright © 2018 Rosewell Shaw and Suzuki. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rosewell Shaw, Amanda
Suzuki, Masataka
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title_full Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title_fullStr Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title_full_unstemmed Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title_short Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
title_sort oncolytic viruses partner with t-cell therapy for solid tumor treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160535/
https://www.ncbi.nlm.nih.gov/pubmed/30298067
http://dx.doi.org/10.3389/fimmu.2018.02103
work_keys_str_mv AT rosewellshawamanda oncolyticvirusespartnerwithtcelltherapyforsolidtumortreatment
AT suzukimasataka oncolyticvirusespartnerwithtcelltherapyforsolidtumortreatment